成人先天性心脏病患者心脏移植与心肝联合移植的单中心结局
本研究回顾性分析了1987至2024年同一中心81例接受心脏移植或心肝联合移植的成人先天性心脏病患者,其中心脏移植67例、心肝联合移植14例。结论认为两种移植均可安全实施且结局良好。
要点
- 两组短期和中期生存可比,心肝联合移植未显示生存劣势。
- 心肝联合移植组急性细胞排斥、抗体介导排斥和慢性排斥的自由度更高,但差异无统计学意义。
核心结论
- 本中心经验表明心脏移植和心肝联合移植均可安全实施并取得良好结局。
研究设计与样本
- 单中心回顾性队列研究,纳入1987至2024年81例成人先天性心脏病患者,其中心脏移植67例(83%)、心肝联合移植14例(17.3%)。
主要发现
- 既往Fontan姑息患者中,心脏移植组Fontan至移植中位时间19年,心肝联合移植组26年。
- 两组短期和中期生存可比。
- 心肝联合移植组急性细胞排斥、抗体介导排斥和慢性排斥的自由度更高,但未达统计学显著性。
关键数值与推荐
- 心肝联合移植14例中13例(92.9%)采用整块技术。
临床怎么用
- 对于合并多器官功能障碍的成人先天性心脏病患者,心脏移植和心肝联合移植均可作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The number of adults with congenital heart disease (ACHD) continues to rise, often presenting with multiorgan dysfunction. This is the largest single-center series reporting outcomes of ACHD who underwent either heart transplantation (HT) or combined heart-liver transplantation (CHLT). METHODS: Adults (aged 18 years and older) with congenital heart disease were identified in retrospective review. All-cause mortality was compared in a Cox-proportional hazards model. Mann-Whitney and χ2 tests were used to analyze differences between groups. RESULTS: Between 1987 and 2024, 81 ACHD underwent HT (n = 67 [83%]) or CHLT (n = 14 [17.3%]) at our institution. There has been an increasing number of HTs and CHLTs performed for ACHD at our institution, especially over the past decade. Patients who underwent CHLT were more likely to have single-ventricle physiology (57% vs 20% for CHLT vs HT, respectively; P = .007). Amongst patients palliated with prior Fontan, the median time between Fontan and transplant was 19 years for HT and 26 years for CHLT. The en bloc technique was used for 13 of 14 patients who underwent CHLT (92.9%). Median crossclamp time and total heart ischemic time were similar between HT and CHLT (P = .20 and P = .19, respectively). Short- and midterm survival were comparable for patients who underwent CHLT and HT. CHLT recipients exhibited a higher degree of freedom from acute cellular rejection, antibody-mediated rejection, and chronic rejection, although this did not reach statistical significance when compared to HT recipients. CONCLUSIONS: Our experience demonstrates that both HT and CHLT can be performed safely with excellent outcomes.
引用
- Mullis DM, Krishnan A, Vargas NM, et al. Outcomes of adults with congenital heart disease undergoing heart and heart-liver transplantation: A single-center experience. J Thorac Cardiovasc Surg. 2026. PMID: 42092508. doi:10.1016/j.jtcvs.2026.03.614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。